According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hyundai plans to invest $15.5 billion in India by 2032.
Secured an order for 100,000 drone batteries, Enovix (ENVX.US) surged more than 17% after hours.
Enovix surged over 17% in after-hours trading on Tuesday after the company announced it had received an initial order of 100,000 batteries from an unnamed multinational drone system supplier.
Financial Report Soared 322% but Shares Fell Nearly 4%: Technical Death Cross Suppresses APLD (APLD.US)
App’s Q1 revenue reached $300 millions, surpassing expectations. However, due to weakness in tech stocks and a technical death cross, the stock price fell by 3.78%. Analysts maintain a buy rating and are closely watching whether the key support level at $19.5 can hold.
Getty bankruptcy privatization: AI impact collapses a 5 billion empire
Getty Images has filed for bankruptcy due to the impact of AI and a debt crisis, with its stock price plummeting by 99.95%. The family and Koch Equity have injected $533 millions for privatization, aiming to transition toward AI training authorization.
Crypto prices
More
